ArticleOncology letters2015
Survivin expression in lung cancer: Association with smoking, histological types and pathological stages.
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Cost-effectiveness of lung cancer screening and treatment methods: a systematic review of systematic reviews.BMC health services research · 2017Pooled it
- Survivin protein expression is involved in the progression of non-small cell lung cancer in Asians: a meta-analysis.BMC cancer · 2016Pooled it
- IAPs in cancers: molecular mechanisms, clinical prognostic value, and translational therapeutic potential.Journal of translational medicine · 2026Review
- Immunohistochemical Expression of Survivin and Vascular Endothelial Growth Factor in Cervical Squamous Cell Carcinoma.Indian journal of surgical oncology · 2025Article
- Stem cells, Notch-1 signaling, and oxidative stress: a hellish trio in cancer development and progression within the airways. Is there a role for natural compounds?Carcinogenesis · 2024Review
- Article
- Survivin in lung cancer: a potential target for therapy and prevention-a narrative review.Translational lung cancer research · 2024Review
- Zerumbone-incorporated liquid crystalline nanoparticles inhibit proliferation and migration of non-small-cell lung cancer in vitro.Naunyn-Schmiedeberg's archives of pharmacology · 2024Article
- Progress in non-viral localized delivery of siRNA therapeutics for pulmonary diseases.Acta pharmaceutica Sinica. B · 2023Review
- Recent Advances in Lung Cancer Therapy Based on Nanomaterials: A Review.Current medicinal chemistry · 2023Review
- Identifying General Tumor and Specific Lung Cancer Biomarkers by Transcriptomic Analysis.Biology · 2022Article
- Circulating Survivin Protein Levels in Lung Cancer Patients Treated With Platinum-Based Chemotherapy.Pathology oncology research : POR · 2021Article
- Role of Napsin A and Survivin Immunohistochemical Expression in Bronchogenic Adenocarcinoma.Asian Pacific journal of cancer prevention : APJCP · 2020Article
- Differential expression of lung adenocarcinoma transcriptome with signature of tobacco exposure.Journal of applied genetics · 2020Article
- Joint Transcriptomic Analysis of Lung Cancer and Other Lung Diseases.Frontiers in genetics · 2019Article
- Epigenetic mechanism of survivin dysregulation in human cancer.Science China. Life sciences · 2018Review
- CT45A1 siRNA silencing suppresses the proliferation, metastasis and invasion of lung cancer cells by downregulating the ERK/CREB signaling pathway.Molecular medicine reports · 2017Article
- Identification of a RNA-Seq based prognostic signature with five lncRNAs for lung squamous cell carcinoma.Oncotarget · 2017Article
- Factors that may influence polymorphous low-grade adenocarcinoma growth.Virchows Archiv : an international journal of pathology · 2017Article
- Insights into Novel Prognostic and Possible Predictive Biomarkers of Lung Neuroendocrine Tumors.Cancer genomics & proteomicsReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Survivin is expressed in the nucleus and/or cytoplasm of various malignant cells. Nuclear survivin is critical for the completion of mitosis, while cytoplasmic survivin functions as an inhibitor of apoptosis. The expression of survivin has been reported to be associated with the aggressiveness of certain types of cancer. The present study examined the association between cigarette smoking history and the expression of survivin and Ki-67 in lung adenocarcinomas of pathological (p) stages I, II and III. The expression of survivin and Ki-67 in adenocarcinomas was also compared with that of other p-stage I lung cancers, including squamous cell carcinoma (SqCC), large cell neuroendocrine carcinoma (LCNEC) and small cell carcinoma (SmCCs), of patients with a smoking history. In adenocarcinomas at p-stage I, labeling indices (LIs) of nuclear survivin and Ki-67 were significantly higher in tissue samples from smokers than those from non-smokers; however, the nuclear survivin and Ki-67 LIs in p-stage II and III adenocarcinomas from non-smokers and smokers were similar to those in p-stage I adenocarcinomas of smokers. The nuclear survivin and Ki-67 LIs in adenocarcinomas of smokers at p-stage I were lower than those in SqCCs, LCNECs and SmCCs of smokers at the same stage. Smokers with adenocarcinoma also exhibited a higher survival rate compared with that of smokers with SqCCs, LCNECs and SmCCs. The present results indicated that a history of smoking is associated with increased nuclear survivin and Ki-67 expression in lung adenocarcinomas of p-stage I, but not p-stages II or III. In addition it was revealed that, in smokers, the nuclear survivin and Ki-67 expression in p-stage I adenocarcinomas was lower than that of other p-stage I lung cancer types, and was associated with an enhanced survival rate. In conclusion, smoking is associated with the histogenesis of lung adenocarcinoma but not with the development of lung adenocarcinoma, based on the nuclear expression levels of Ki-67 and survivin.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.